AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cognition Therapeutics Completes Phase 2 Enrollment of Zervimesine in Early Alzheimer's Disease Study
ByAinvest
Thursday, Nov 13, 2025 7:38 am ET1min read
Cognition Therapeutics has completed enrollment in its Phase 2 study of zervimesine (CT1812) in early Alzheimer's disease, with 540 participants and additional patients in the final stages of screening. The study aims to assess the safety and activity of the drug in participants with mild cognitive impairment or early Alzheimer's disease. Topline results are expected after 18 months of treatment, and the drug has the potential to be an important part of Alzheimer's treatment due to its oral dosing and safety profile.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet